Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that
exceeds 35 years in young patients, but its natural history might be interrupted by …

Abstract Disease Overview Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …

Overview: Essential thrombocythemia is a Janus kinase 2 (JAK2) mutation-prevalent
myeloproliferative neoplasm characterized by clonal thrombocytosis; clinical course is often …

Arachidonic acid is one of the most abundant and ubiquitous ω-6 polyunsaturated fatty acid,
present in esterified form in the membrane phospholipids of all mammalian cells and …

Disease overview Polycythemia vera (PV) and essential thrombocythemia (ET) are
myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and …

Myeloproliferative neoplasms are associated with increased risk for thrombotic
complications. These conditions most commonly involve somatic mutations in genes that …

Clonal hematopoiesis arises from somatic mutations that provide a fitness advantage to
hematopoietic stem cells and the outgrowth of clones of blood cells. Clonal hematopoiesis …

Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), polycythemia
vera, essential thrombocythemia, and primary myelofibrosis, are hematopoietic stem cell …

In 2021, we reached the 50th anniversary of the publication of Sir John Vane's seminal
paper in Nature New Biology describing the experiments supporting his mechanistic …

A state‐of‐the‐art lecture titled “Myeloproliferative Neoplasm‐associated Thrombosis” was
presented at the ISTH congress in 2021. We summarize here the main points of the lecture …